We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.

This study has been terminated.
ClinicalTrials.gov Identifier:
First Posted: September 20, 2005
Last Update Posted: June 9, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Nantes University Hospital
Comparison between FDG-PET and MRI for the assessment of response to intensive chemotherapy in multiple myeloma patients.

Condition Intervention
Multiple Myeloma Drug: FDG = fluorodeoxyglucose

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic

Resource links provided by NLM:

Further study details as provided by Nantes University Hospital:

Enrollment: 0
Study Start Date: March 2005
Study Completion Date: December 2006
Detailed Description:
First whole body FDG-PET scan and MRI before the start of the treatment. Second whole body FDG-PET scan and MRI after the end of the treatment. On a basis of patient, comparison between PET and MRI will be done tumoral site by site. Sensitivity, Specificity will be estimated for both techniques. In case of discrepancy, another imaging method or biopsy (if easy to perform) will be serve as standard of reference. Kappa coefficients and Mc Nemar test will be performed to compare the two methods. FDG = fluorodeoxyglucose FLUCIS® (Schering-CisBio® international)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients from 18 to 65 years old.
  • De novo histologically proven multiple myeloma.

Exclusion Criteria:

  • No history of another cancer or of HIV
  • No history of renal failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00200668

Nantes University Hospital
Nantes, France, 44093
Sponsors and Collaborators
Nantes University Hospital
Principal Investigator: Olivier Couturier, MD Nantes University Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00200668     History of Changes
Other Study ID Numbers: BRD/04/6-H
First Submitted: September 12, 2005
First Posted: September 20, 2005
Last Update Posted: June 9, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Fluorodeoxyglucose F18
Molecular Mechanisms of Pharmacological Action